Capricor Therapeutics, Inc. (CAPR) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Capricor Therapeutics, Inc. (CAPR) stock forecast summary
Our AI ranks Capricor Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Capricor Therapeutics, Inc. is a small-cap company with a market capitalization of $383M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/B Ratio of 1.56x is the lowest of the 43 peers that report one.
A per-ticker accuracy statistic for CAPR is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CAPR included.
Follow CAPR freeCAPR price chart and AI forecast
How CAPR ranks among 5380 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Capricor Therapeutics, Inc. (CAPR) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | CAPR | Rank |
|---|---|---|
| Market Cap | $383M | 60/60 |
| P/B Ratio | 1.56x | 43/43 |
| EPS | $-2.39 | – |
| Book Value/Share | $4.24 | – |
| FCF/Share | $-1.98 | – |
Profitability & Margins
| Metric | CAPR | Rank |
|---|---|---|
| ROE | -52.6% | 25/33 |
| ROA | -35.1% | 32/39 |
| ROIC | -40.2% | 31/41 |
| Operating Margin | -607.1% | 30/33 |
| Net Margin | -581.4% | 30/33 |
| EBT Margin | -570.6% | 37/40 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | CAPR | Rank |
|---|---|---|
| Current Ratio | 7.35x | 13/50 |
| D/E Ratio | 0.50x | 26/43 |
| Financial Leverage | 1.50x | 26/43 |
| Interest Coverage | -40.9x | 30/36 |
| Working Capital | $209M | 46/50 |
Cash Flow
| Metric | CAPR | Rank |
|---|---|---|
| Operating Cash Flow | -$104M | 34/49 |
| Free Cash Flow | -$115M | 27/39 |
| Capital Spending | -$11M | 17/39 |
Income Statement
| Metric | CAPR | Rank |
|---|---|---|
| Operating Income | -$135M | 24/41 |
| Net Income | -$129M | 23/40 |
| R&D Expense | $100M | 45/48 |
Dividend & Shareholder Information
| Metric | CAPR | Rank |
|---|---|---|
| Shares Outstanding | 58M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $242M | 65.7% of assets |
| Cash & Short-term Investments | $21M | 5.7% of assets |
| Total Liabilities | $123M | 33.2% of assets |
| Short-term Debt | $30M | 8.1% of assets |
CAPR quarterly financials and insider trading
Capricor Therapeutics, Inc. (CAPR) industry peers
Companies classified under the same SEC industry code as Capricor Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CAPR Capricor Therapeutics, Inc. | ▲ | $383M |
| LLY Eli Lilly & Co | ▲ | $1.14T |
| JNJ Johnson & Johnson | ▼ | $611.90B |
| ONC Beone Medicines Ltd. | ▶ | $519.53B |
| ABBV Abbvie Inc. | ▼ | $501.24B |
| MRK Merck & Co., Inc. | ▼ | $363.59B |
| NVS Novartis Ag | ▼ | $280.27B |
| GSK Gsk Plc | ▼ | $206.58B |
| ABT Abbott Laboratories | ▶ | $179.37B |
| PFE Pfizer Inc | ▲ | $166.49B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $126.35B |
| BMY Bristol Myers Squibb Co | ▼ | $121.09B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $80.14B |
| SNY Sanofi | ▼ | $48.50B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.45B |
| RPRX Royalty Pharma Plc | ▲ | $33.92B |
| ZTS Zoetis Inc. | ▼ | $31.11B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $30.24B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $30.04B |
| ATHE Alterity Therapeutics Ltd | ▶ | $25.65B |
| ZLAB Zai Lab Ltd | ▼ | $25.26B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.28B |
| UTHR United Therapeutics Corp | ▼ | $23.16B |
| INSM Insmed Inc | ▶ | $21.36B |
| VTRS Viatris Inc | ▶ | $20.03B |
| ASND Ascendis Pharma A/S | ▶ | $14.07B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.61B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.69B |
| CORT Corcept Therapeutics Inc | ▲ | $12.56B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.30B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.07B |
| HCM Hutchmed (China) Ltd | ▶ | $11.76B |
| ELAN Elanco Animal Health Inc | ▶ | $11.27B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.64B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.63B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.82B |
| CYTK Cytokinetics Inc | ▶ | $8.82B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.50B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.25B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.10B |
| LEGN Legend Biotech Corp | ▶ | $7.04B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $6.93B |
| ABVX Abivax S.A. | ▼ | $6.91B |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.67B |
| ALKS Alkermes Plc. | ▶ | $6.56B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.04B |
| BLTE Belite Bio, Inc | ▲ | $6.01B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.97B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.88B |
| BLRX Biolinerx Ltd. | ▶ | $5.43B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.19B |
| ERAS Erasca, Inc. | ▲ | $5.14B |
| TVTX Travere Therapeutics, Inc. | ▲ | $5.02B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $4.98B |
| COGT Cogent Biosciences, Inc. | ▼ | $4.88B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.88B |
| MANE Veradermics, Inc | ▲ | $4.74B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.68B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.18B |
Where CAPR sits on the market map
Capricor Therapeutics, Inc. (CAPR) stock news
Loading...
Capricor Therapeutics, Inc. (CAPR) stock forecast FAQ
What is the Capricor Therapeutics, Inc. (CAPR) stock forecast?
Our AI ranks Capricor Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Capricor Therapeutics, Inc. stock predictions?
A per-ticker accuracy statistic for CAPR is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Capricor Therapeutics, Inc. forecasts updated?
Capricor Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Capricor Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, CAPR included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.